A Phase 3 interventional study of Matching Placebo for Upadacitinib and Upadacitinib in Crohn's Disease, sponsored by AbbVie. Completed at 428 sites in 48 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-08-15.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Crohn Disease by AbbVie — 6 open to participants now, 14 under way, 6 of them phase 3. Crohn Disease · AbbVie.
Among the 55 studies in Crohn Disease by AbbVie, this one is the 5th largest by enrollment of the 27 interventional ones that give a count, is one of 6 that started in 2017, is one of 16 in phase 3, and was the 32nd registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →6 of the 55 studies in Crohn Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Canada, Israel and 2 more countries
Ages 18–75
AbbVie · Sites in Italy
Ages 18+
AbbVie · Sites in Belgium
Ages 18+
AbbVie · Sites in United States, Austria, Belgium and 30 more countries
Ages 18–75
AbbVie · Sites in United States, Belgium, Bulgaria and 18 more countries
Ages 2–17
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 6 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 624 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 220 across the 27 interventional studies, 252 across the 26 observational. Of the 38 that completed or were terminated, 28 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
2 of the studies in Crohn Disease by AbbVie that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 55 studies in Crohn Disease by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and severely active Crohn's disease (CD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received upadacitinib matching placebo tablets, orally, once daily (QD) for 12 weeks during the Double-blind (DB) Induction Period.
Drug: Matching Placebo for Upadacitinib
Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the DB Induction Period.
Drug: Upadacitinib
Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks during the Open-label (OL) Induction Period.
Drug: Upadacitinib
Participants received upadacitinib 45 mg tablets, orally, QD for 12 weeks (until Week 24) during the Extended Treatment (ET) Period. Participants who received placebo in Part 1 and did not achieve clinical response at Week 12 were included in this group.
Drug: Upadacitinib
Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received DB upadacitinib 45 mg in Part 1 and did not achieve clinical response at Week 12 were included in this group.
Drug: Upadacitinib
Participants received upadacitinib 30 mg tablets, orally, QD for 12 weeks (until Week 24) during the ET Period. Participants who received OL upadacitinib 45 mg during Part 2 and did not achieve clinical response at Week 12 were included in this group.
Drug: Upadacitinib
Matching placebo tablets
Upadacitinib tablets
Also known as: ABT-494, RINVOQ®
Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12
The CDAI was used to evaluate the activity of Crohn's disease. Clinical remission per CDAI is defined as CDAI \<150. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19 (NRI-C).
Time frame: Week 12
Percentage of Participants With Endoscopic Response at Week 12
Endoscopic response was defined as greater than 50% decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) from Baseline of the induction study (or for participants with an SES-CD of 4 at Baseline of the induction study, at least a 2-point reduction from Baseline), as scored by Central Reviewer. SES-CD is calculated based on the sum of individual segment values for four endoscopic variables (presence and size of ulcers, ulcerated surface, affected surface and presence of narrowing). Each variable in each segment is scored 0 to 3 resulting in SES-CD values ranging from 0 to 56 with higher scores indicating more severe disease. Results were based on NRI-C.
Time frame: Baseline to Week 12
Number of Participants With Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not the event is considered causally related to the use of the product.
Time frame: From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks)
Percentage of Participants With Clinical Remission Per Patient-Reported Outcomes (PROs) at Week 12
Clinical remission per PROs was defined as average daily very soft or liquid stool frequency (SF) ≤2.8 and average daily abdominal pain (AP) score ≤1.0 and both not greater than Baseline. The number of soft or liquid stools and abdominal pain rated on a scale of 0=none to 3=severe were recorded in an electronic diary. Results were based on NRI-C.
Time frame: Baseline to Week 12
Percentage of Participants With Endoscopic Remission at Week 12
Endoscopic remission was defined per SES-CD. SES-CD ≤4 and at least 2-point reduction from Baseline and no subscore \>1 in any individual variable, as scored by Central Reviewer. SES-CD is calculated based on the sum of individual segment values for four endoscopic variables (presence and size of ulcers, ulcerated surface, affected surface and presence of narrowing). Each variable in each segment is scored 0 to 3 resulting in SES-CD values ranging from 0 to 56 with higher scores indicating more severe disease. Results were based on NRI-C.
Time frame: Baseline to Week 12
Percentage of Participants Who Discontinued Corticosteroid Use for Crohn's Disease (CD) and Achieved Clinical Remission Per CDAI at Week 12, in Participants Taking Corticosteroids at Baseline
As prespecified in the protocol, this outcome measure was planned to be assessed in participants taking corticosteroids at Baseline. Clinical remission per CDAI: CDAI \<150. The CDAI is used to evaluate the activity of Crohn's disease. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.
Time frame: Week 12
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score at Week 12
The FACIT-F questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. The responses to the 13 items on the FACIT-F questionnaire are each measured on a 5-point Likert scale. The responses to the answers are the following: 0= not at all; 1= a little bit; 2= somewhat; 3= quite a bit; 4=very much. Thus, the total score ranges from 0 to 52. High scores represent less fatigue. A positive change from Baseline indicates improvement.
Time frame: Baseline and Week 12
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 12
The IBDQ is a disease-specific instrument composed of 32 Likert-scaled items. The IBDQ scale contains 4 component subscales: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items), and social function(5 items). Each item is scored on a 7-point scale where: 1=worst to 7= best. The total score ranges from 32 to 224, with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.
Time frame: Baseline and Week 12
Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 2
CR-100 is defined as a decrease of at least 100 points in CDAI from Baseline at Week 2. The CDAI is used to evaluate the activity of Crohn's disease. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.
Time frame: Baseline to Week 2
Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 12
CR-100 is defined as a decrease of at least 100 points in CDAI from Baseline at Week 12. The CDAI is used to evaluate the activity of Crohn's disease. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.
Time frame: Baseline to Week 12
Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 4
The CDAI was used to evaluate the activity of Crohn's disease. Clinical remission per CDAI is defined as CDAI \<150. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.
Time frame: Week 4
Percentage of Participants With Hospitalizations Due to Crohn's Disease (CD) During Part 1 (12-week Double-blind Induction Period)
Time frame: Up to Week 12 in Part 1: Double-blind Induction Period
Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs) at Week 12, in Participants With EIMs at Baseline
EIMs are defined as manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver. Results were based on NRI-C.
Time frame: Week 12
| Milestone | Part 1 (Double-blind): Placebo | Part 1 (Double-blind): Upadacitinib 45 mg | Part 2 (Open-label): Upadacitinib 45 mg | Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo | Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg | Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg |
|---|---|---|---|---|---|---|
| Started | 171 | 324 | 129 | 0 | 0 | 0 |
| Completed | 149 | 291 | 123 | 0 | 0 | 0 |
| Not completed | 22 | 33 | 6 | 0 | 0 | 0 |
| Withdrew: Adverse event | 5 | 17 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 8 | 8 | 3 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 8 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 1 | 3 | 1 | 0 | 0 | 0 |
| Milestone | Part 1 (Double-blind): Placebo | Part 1 (Double-blind): Upadacitinib 45 mg | Part 2 (Open-label): Upadacitinib 45 mg | Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo | Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg | Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 78 | 69 | 14 |
| Completed | 0 | 0 | 0 | 67 | 51 | 8 |
| Not completed | 0 | 0 | 0 | 11 | 18 | 6 |
| Withdrew: Adverse event | 0 | 0 | 0 | 8 | 5 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 0 | 5 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 2 | 6 | 3 |
| Withdrew: Coronavirus disease (covid-19) logistical restrictions | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 1 | 1 | 1 |
The CDAI was used to evaluate the activity of Crohn's disease. Clinical remission per CDAI is defined as CDAI \<150. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19 (NRI-C).
| percentage of participants | Part 1 (Double Blind): Placebo | Part 1 (Double Blind): Upadacitinib 45 mg |
|---|---|---|
| Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 | 21.1 (14.9 to 27.2) | 38.9 (33.6 to 44.2) |
Endoscopic response was defined as greater than 50% decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) from Baseline of the induction study (or for participants with an SES-CD of 4 at Baseline of the induction study, at least a 2-point reduction from Baseline), as scored by Central Reviewer. SES-CD is calculated based on the sum of individual segment values for four endoscopic variables (presence and size of ulcers, ulcerated surface, affected surface and presence of narrowing). Each variable in each segment is scored 0 to 3 resulting in SES-CD values ranging from 0 to 56 with higher scores indicating more severe disease. Results were based on NRI-C.
| percentage of participants | Part 1 (Double Blind): Placebo | Part 1 (Double Blind): Upadacitinib 45 mg |
|---|---|---|
| Percentage of Participants With Endoscopic Response at Week 12 | 3.5 (0.8 to 6.3) | 34.6 (29.4 to 39.8) |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not the event is considered causally related to the use of the product.
| Participants | Part 1 (Double-blind): Placebo | Part 1 (Double-blind): Upadacitinib 45 mg | Part 2 (Open-label): Upadacitinib 45 mg | Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo | Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg | Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg |
|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events | 112 | 221 | 86 | 53 | 45 | 9 |
Clinical remission per PROs was defined as average daily very soft or liquid stool frequency (SF) ≤2.8 and average daily abdominal pain (AP) score ≤1.0 and both not greater than Baseline. The number of soft or liquid stools and abdominal pain rated on a scale of 0=none to 3=severe were recorded in an electronic diary. Results were based on NRI-C.
| percentage of participants | Part 1 (Double Blind): Placebo | Part 1 (Double Blind): Upadacitinib 45 mg |
|---|---|---|
| Percentage of Participants With Clinical Remission Per Patient-Reported Outcomes (PROs) at Week 12 | 14.0 (8.8 to 19.2) | 39.8 (34.5 to 45.1) |
Endoscopic remission was defined per SES-CD. SES-CD ≤4 and at least 2-point reduction from Baseline and no subscore \>1 in any individual variable, as scored by Central Reviewer. SES-CD is calculated based on the sum of individual segment values for four endoscopic variables (presence and size of ulcers, ulcerated surface, affected surface and presence of narrowing). Each variable in each segment is scored 0 to 3 resulting in SES-CD values ranging from 0 to 56 with higher scores indicating more severe disease. Results were based on NRI-C.
| percentage of participants | Part 1 (Double Blind): Placebo | Part 1 (Double Blind): Upadacitinib 45 mg |
|---|---|---|
| Percentage of Participants With Endoscopic Remission at Week 12 | 2.3 (0.1 to 4.6) | 19.1 (14.9 to 23.4) |
As prespecified in the protocol, this outcome measure was planned to be assessed in participants taking corticosteroids at Baseline. Clinical remission per CDAI: CDAI \<150. The CDAI is used to evaluate the activity of Crohn's disease. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.
| percentage of participants | Part 1 (Double Blind): Placebo | Part 1 (Double Blind): Upadacitinib 45 mg |
|---|---|---|
| Percentage of Participants Who Discontinued Corticosteroid Use for Crohn's Disease (CD) and Achieved Clinical Remission Per CDAI at Week 12, in Participants Taking Corticosteroids at Baseline | 11.7 (3.5 to 19.8) | 34.3 (25.3 to 43.2) |
The FACIT-F questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. The responses to the 13 items on the FACIT-F questionnaire are each measured on a 5-point Likert scale. The responses to the answers are the following: 0= not at all; 1= a little bit; 2= somewhat; 3= quite a bit; 4=very much. Thus, the total score ranges from 0 to 52. High scores represent less fatigue. A positive change from Baseline indicates improvement.
| score on a scale | Part 1 (Double Blind): Placebo | Part 1 (Double Blind): Upadacitinib 45 mg |
|---|---|---|
| Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Total Score at Week 12 | 3.9 ± 0.97 | 11.4 ± 0.69 |
The IBDQ is a disease-specific instrument composed of 32 Likert-scaled items. The IBDQ scale contains 4 component subscales: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items), and social function(5 items). Each item is scored on a 7-point scale where: 1=worst to 7= best. The total score ranges from 32 to 224, with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.
| score on a scale | Part 1 (Double Blind): Placebo | Part 1 (Double Blind): Upadacitinib 45 mg |
|---|---|---|
| Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 12 | 21.6 ± 3.02 | 46.0 ± 2.14 |
CR-100 is defined as a decrease of at least 100 points in CDAI from Baseline at Week 2. The CDAI is used to evaluate the activity of Crohn's disease. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.
| percentage of participants | Part 1 (Double Blind): Placebo | Part 1 (Double Blind): Upadacitinib 45 mg |
|---|---|---|
| Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 2 | 12.4 (7.4 to 17.4) | 33.2 (28.0 to 38.3) |
CR-100 is defined as a decrease of at least 100 points in CDAI from Baseline at Week 12. The CDAI is used to evaluate the activity of Crohn's disease. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to about 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.
| percentage of participants | Part 1 (Double Blind): Placebo | Part 1 (Double Blind): Upadacitinib 45 mg |
|---|---|---|
| Percentage of Participants Achieving Clinical Response 100 (CR-100) at Week 12 | 27.5 (20.8 to 34.2) | 50.5 (45.1 to 56.0) |
The CDAI was used to evaluate the activity of Crohn's disease. Clinical remission per CDAI is defined as CDAI \<150. The CDAI is calculated on the basis of a one-week evaluation of 8 items: frequency of liquid or very soft stool, abdominal pain, complications of Crohn's disease (e.g., uveitis, arthritis, fistula, and abscess), abdominal mass, hematocrit, body weight, use of antidiarrheals, and general condition. Total score ranges from 0 to 600. Higher CDAI scores indicate more severe disease. CDAI scores below 150 represent remission and scores over 450 represent very severe Crohn's disease. Results were based on NRI-C.
| percentage of participants | Part 1 (Double Blind): Placebo | Part 1 (Double Blind): Upadacitinib 45 mg |
|---|---|---|
| Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 4 | 17.7 (11.9 to 23.4) | 29.6 (24.7 to 34.6) |
| percentage of participants | Part 1 (Double Blind): Placebo | Part 1 (Double Blind): Upadacitinib 45 mg |
|---|---|---|
| Percentage of Participants With Hospitalizations Due to Crohn's Disease (CD) During Part 1 (12-week Double-blind Induction Period) | 8.8 (4.5 to 13.0) | 6.2 (3.6 to 8.8) |
EIMs are defined as manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver. Results were based on NRI-C.
| percentage of participants | Part 1 (Double Blind): Placebo | Part 1 (Double Blind): Upadacitinib 45 mg |
|---|---|---|
| Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs) at Week 12, in Participants With EIMs at Baseline | 21.7 (11.2 to 32.1) | 32.8 (24.8 to 40.9) |
Collected over From first dose of study drug until 30 days following last dose of study drug (up to approximately 28 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 (Double-blind): Placebo | 0/171 (0%) | 17/171 (9.9%) | 69/171 (40.4%) |
| Part 1 (Double Blind): Upadacitinib 45 mg | 1/324 (0.3%) | 30/324 (9.3%) | 126/324 (38.9%) |
| Part 2 (Open Label): Upadacitinib 45 mg | 0/129 (0%) | 9/129 (7%) | 44/129 (34.1%) |
| Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo | 0/78 (0%) | 11/78 (14.1%) | 29/78 (37.2%) |
| Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg | 0/69 (0%) | 7/69 (10.1%) | 12/69 (17.4%) |
| Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg | 0/14 (0%) | 5/14 (35.7%) | 7/14 (50%) |
| Event | Part 1 (Double-blind): Placebo | Part 1 (Double Blind): Upadacitinib 45 mg | Part 2 (Open Label): Upadacitinib 45 mg | Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo | Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg | Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg |
|---|---|---|---|---|---|---|
| CROHN'S DISEASEGastrointestinal disorders | 10/171 | 7/324 | 4/129 | 3/78 | 4/69 | 3/14 |
| ABDOMINAL ABSCESSInfections and infestations | 0/171 | 0/324 | 0/129 | 0/78 | 0/69 | 1/14 |
| GASTROENTERITISInfections and infestations | 0/171 | 0/324 | 0/129 | 0/78 | 0/69 | 1/14 |
| HYPOKALAEMIAMetabolism and nutrition disorders | 0/171 | 0/324 | 0/129 | 0/78 | 0/69 | 1/14 |
| COVID-19 PNEUMONIAInfections and infestations | 0/171 | 0/324 | 2/129 | 0/78 | 0/69 | 0/14 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 0/171 | 0/324 | 0/129 | 0/78 | 1/69 | 0/14 |
| LEUKOPENIABlood and lymphatic system disorders | 0/171 | 0/324 | 0/129 | 0/78 | 1/69 | 0/14 |
| SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders | 0/171 | 1/324 | 1/129 | 0/78 | 1/69 | 0/14 |
| NEPHROLITHIASISRenal and urinary disorders | 0/171 | 1/324 | 0/129 | 0/78 | 1/69 | 0/14 |
| ABDOMINAL PAINGastrointestinal disorders | 0/171 | 1/324 | 0/129 | 1/78 | 0/69 | 0/14 |
| Event | Part 1 (Double-blind): Placebo | Part 1 (Double Blind): Upadacitinib 45 mg | Part 2 (Open Label): Upadacitinib 45 mg | Part 3 (Extended Treatment DB): Upadacitinib 45 mg From Part 1 DB Placebo | Part 3 (Extended Treatment DB): Upadacitinib 30 mg From Part 1 DB Upadacitinib 45 mg | Part 3 (Extended Treatment OL): Upadacitinib 30 mg From Part 2 OL Upadacitinib 45 mg |
|---|---|---|---|---|---|---|
| NAUSEAGastrointestinal disorders | 8/171 | 15/324 | 3/129 | 3/78 | 1/69 | 2/14 |
| VOMITINGGastrointestinal disorders | 4/171 | 8/324 | 0/129 | 0/78 | 0/69 | 2/14 |
| ACNESkin and subcutaneous tissue disorders | 4/171 | 15/324 | 18/129 | 5/78 | 0/69 | 0/14 |
| CROHN'S DISEASEGastrointestinal disorders | 13/171 | 12/324 | 5/129 | 5/78 | 4/69 | 1/14 |
| INFLUENZAInfections and infestations | 2/171 | 9/324 | 1/129 | 2/78 | 3/69 | 1/14 |
| BLOOD PHOSPHORUS DECREASEDInvestigations | 0/171 | 1/324 | 1/129 | 0/78 | 0/69 | 1/14 |
| FISTULA DISCHARGEMusculoskeletal and connective tissue disorders | 0/171 | 0/324 | 0/129 | 0/78 | 0/69 | 1/14 |
| INSOMNIAPsychiatric disorders | 2/171 | 5/324 | 1/129 | 1/78 | 0/69 | 1/14 |
| HAEMATURIARenal and urinary disorders | 0/171 | 0/324 | 0/129 | 0/78 | 0/69 | 1/14 |
| ALOPECIASkin and subcutaneous tissue disorders | 0/171 | 3/324 | 0/129 | 0/78 | 0/69 | 1/14 |
Intent-to-Treat (ITT) Population for the 12-week DB Induction Period (Part 1) i.e., ITT1 included all randomized participants who received at least one dose of DB study drug during Part 1. ITT Population for the 12-week OL Induction Period (Part 2) i.e., ITT2 included all participants who received at least one dose of study drug in Part 2.
| Age, Continuous(years) | Part 1 (Double Blind): Placebo | Part 1 (Double Blind): Upadacitinib 45 mg | Part 2 (Open Label): Upadacitinib 45 mg | Total |
|---|---|---|---|---|
| Part 1 (Double Blind) | 37.5 (18 to 74) | 38.4 (18 to 73) | — | 38.1 (18 to 74) |
| Part 2 (Open Label) | — | — | 39.1 (18 to 68) | 39.1 (18 to 68) |
| Sex: Female, Male(Participants) | Part 1 (Double Blind): Placebo | Part 1 (Double Blind): Upadacitinib 45 mg | Part 2 (Open Label): Upadacitinib 45 mg | Total |
|---|---|---|---|---|
| Female | 75 | 155 | 60 | 290 |
| Male | 96 | 169 | 69 | 334 |
| Ethnicity (NIH/OMB)(Participants) | Part 1 (Double Blind): Placebo | Part 1 (Double Blind): Upadacitinib 45 mg | Part 2 (Open Label): Upadacitinib 45 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 8 | 24 | 8 | 40 |
| Not Hispanic or Latino | 163 | 300 | 121 | 584 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1 (Double Blind): Placebo | Part 1 (Double Blind): Upadacitinib 45 mg | Part 2 (Open Label): Upadacitinib 45 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | 2 |
| Asian | 38 | 69 | 11 | 118 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 19 | 5 | 30 |
| White | 126 | 230 | 113 | 469 |
| More than one race | 0 | 5 | 0 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
Showing the first 100 of 428 sites across 48 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing, please refer to the link below.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · vivli.org
Ran from Nov 2017 to primary completion in Aug 2021, 44 months.
Results were first posted in Aug 2022, 1 year after primary completion.
Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 44 months is close to that.
Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib